145 related articles for article (PubMed ID: 37062211)
21. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
[TBL] [Abstract][Full Text] [Related]
22. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
23. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
24. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
25. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
27. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Ponziani FR; Bhoori S; Germini A; Bongini M; Flores M; Sposito C; Facciorusso A; Gasbarrini A; Mazzaferro V
Liver Int; 2016 Jul; 36(7):1033-42. PubMed ID: 26709844
[TBL] [Abstract][Full Text] [Related]
28. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
29. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Semrad TJ; Eddings C; Pan CX; Lau DH; Gandara D; Beckett L; Lara PN
Invest New Drugs; 2012 Oct; 30(5):2001-7. PubMed ID: 22015991
[TBL] [Abstract][Full Text] [Related]
30. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
31. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
32. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
33. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
35. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Yu X; Guo G; Li X; Zhang C; Huang L; Fang D; Song Y; Zhang X; Zhou L
Medicine (Baltimore); 2015 Aug; 94(34):e1361. PubMed ID: 26313773
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
38. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
